Breakthrough new coronary pneumonia drug may be available earlier than vaccine

Some of the new coronary pneumonia vaccines are now working together around the world, and if they are eventually approved and put on the market, they will stop the pandemic and give people the group immunity they need,media reported. But the day seems to be a long way off, and now drugs that promise to cure new coronary pneumonia and prevent infection may be a better option.

Breakthrough new coronary pneumonia drug may be available earlier than vaccine

Infographic

It is reported that the drugs have entered the human testing stage, may be approved as early as September, this time earlier than any candidate vaccine time.

These new coronapneumonia drugs are not like Redseve, hydroxychloroquine or anyother thing we’ve heard of, they are monoclonal antibodies designed to prevent the virus from sticking to cell receptors. These antibodies are produced when the immune system first comes into contact with pathogens or vaccines.

High-risk patients, including the elderly, people with underlying diseases

You may not be able to produce antibodies yourself, but monoclonal antibody drugs may help. These drugs can not only neutralise the infection but also block the infection in the first place. As long as these antibodies circulate in the blood, they can fight SARS-CoV-2. That’s the advantage of vaccines over monoclonal antibody therapy, because they teach the body to make their own antibodies and provide more durable immunity, but vaccines don’t work for people who are already sick.

Eli Lilly is one of several drugmakers that have begun clinical trials of monoclonal antibodies. A few weeks ago, the company launched a phase i-phase clinical trial of LY-CoV555 drug candidates in the United States. The drug was tested in laboratory tests for the new coronavirus, allowing the company to continue human trials. In addition, the company is testing a candidate drug called JS016, a drug developed in partnership with Chinese drugmaker Shanghai Junshi Biotech Co., Ltd. Daniel Skovronsky, chief scientific officer, told Reuters a few days ago that a third antibody treatment is now in the preclinical stage.

It is understood that the primary goal of these monoclonal antibody treatment is to cure patients with new coronary pneumonia and prevent serious complications.